Seladelpar Beneficial for Patients With Primary Biliary Cholangitis
Percentage of patients with biochemical response was higher in the seladelpar versus placebo group.
Percentage of patients with biochemical response was higher in the seladelpar versus placebo group.
Contact Your Legislators to Address Drug Shortages in Hematology and Oncology Care
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development.…
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.
Published: August 16, 2023Medically Reviewed By: Pamela J. DiPiro, MDBreast cancer is one of the most common forms of cancer and affects almost 300,000 women…
The time is now. Use your VOICE to change the future of cancer as we know it.
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, covering diagnosis, tr …
Chronic stress may help cause the formation of structures called NETs that can help tumors metastasize, a new study in mice suggests.
A novel AI model may accurately predict which patients with cancer may require mental health services during cancer care, according to results from a recent…
A national study led by researchers at MD Anderson Cancer Center and the University of New Mexico Comprehensive Cancer Center found major gaps in breast,…